| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michael J Pontecorvo, Michael D Devous, Michael Navitsky, Ming Lu, Stephen Salloway, Frederick W Schaerf, Danna Jennings, Anupa K Arora, Anne McGeehan, Nathaniel C Lim, Hui Xiong, Abhinay D Joshi, Andrew Siderowf, Mark A Mintu. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28077397. |
the advent of tau-targeted positron emission tomography tracers such as flortaucipir (18f-av-1451, also known as 18f-t807) have made it possible to investigate the sequence of development of tau and amyloid-β in relationship to age, and to the development of cognitive impairment due to alzheimer's disease. |
2017-05-29 |
2023-08-13 |
human |
| Michael J Pontecorvo, Michael D Devous, Michael Navitsky, Ming Lu, Stephen Salloway, Frederick W Schaerf, Danna Jennings, Anupa K Arora, Anne McGeehan, Nathaniel C Lim, Hui Xiong, Abhinay D Joshi, Andrew Siderowf, Mark A Mintu. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28077397. |
in this study, flortaucipir tau and florbetapir amyloid positron emission tomography were obtained for 217 subjects including 16 young and 58 older cognitively normal subjects, 95 subjects with mild cognitive impairment (mini-mental state examination 24-30) and 48 subjects with clinically-defined possible or probable alzheimer's disease (mini-mental state examination >10). |
2017-05-29 |
2023-08-13 |
human |
| Michael J Pontecorvo, Michael D Devous, Michael Navitsky, Ming Lu, Stephen Salloway, Frederick W Schaerf, Danna Jennings, Anupa K Arora, Anne McGeehan, Nathaniel C Lim, Hui Xiong, Abhinay D Joshi, Andrew Siderowf, Mark A Mintu. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28077397. |
finally, within the aβ+ group, increasing levels of flortaucipir tau binding were associated with increased cognitive impairment, as assessed by mini-mental state examination and alzheimer's disease assessment scale. |
2017-05-29 |
2023-08-13 |
human |
| Maiko Ono, Naruhiko Sahara, Katsushi Kumata, Bin Ji, Ruiqing Ni, Shunsuke Koga, Dennis W Dickson, John Q Trojanowski, Virginia M-Y Lee, Mari Yoshida, Isao Hozumi, Yasumasa Yoshiyama, John C van Swieten, Agneta Nordberg, Tetsuya Suhara, Ming-Rong Zhang, Makoto Higuch. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28087578. |
fluorescence microscopy demonstrated intense labelling of non-ghost and ghost tangles with pbb3 and av-1451, while dystrophic neurites were more clearly detected by pbb3 in brains of alzheimer's disease and diffuse neurofibrillary tangles with calcification, characterized by accumulation of all six tau isoforms. |
2017-05-29 |
2023-08-13 |
Not clear |
| Zhen Fan, David J Brooks, Aren Okello, Paul Ediso. An early and late peak in microglial activation in Alzheimer's disease trajectory. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28122877. |
amyloid-β deposition, neuroinflammation and tau tangle formation all play a significant role in alzheimer's disease. |
2017-05-29 |
2023-08-13 |
human |
| Luca Passamonti, Patricia Vázquez Rodríguez, Young T Hong, Kieren S J Allinson, David Williamson, Robin J Borchert, Saber Sami, Thomas E Cope, W Richard Bevan-Jones, P Simon Jones, Robert Arnold, Ajenthan Surendranathan, Elijah Mak, Li Su, Tim D Fryer, Franklin I Aigbirhio, John T O'Brien, James B Row. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28122879. |
the ability to assess the distribution and extent of tau pathology in alzheimer's disease and progressive supranuclear palsy in vivo would help to develop biomarkers for these tauopathies and clinical trials of disease-modifying therapies. |
2017-05-29 |
2023-08-13 |
human |
| Luca Passamonti, Patricia Vázquez Rodríguez, Young T Hong, Kieren S J Allinson, David Williamson, Robin J Borchert, Saber Sami, Thomas E Cope, W Richard Bevan-Jones, P Simon Jones, Robert Arnold, Ajenthan Surendranathan, Elijah Mak, Li Su, Tim D Fryer, Franklin I Aigbirhio, John T O'Brien, James B Row. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28122879. |
we assessed the radiotracer 18f-av-1451 with positron emission tomography imaging to compare the distribution and intensity of tau pathology in 15 patients with alzheimer's pathology (including amyloid-positive mild cognitive impairment), 19 patients with progressive supranuclear palsy, and 13 age- and sex-matched controls. |
2017-05-29 |
2023-08-13 |
human |
| Luca Passamonti, Patricia Vázquez Rodríguez, Young T Hong, Kieren S J Allinson, David Williamson, Robin J Borchert, Saber Sami, Thomas E Cope, W Richard Bevan-Jones, P Simon Jones, Robert Arnold, Ajenthan Surendranathan, Elijah Mak, Li Su, Tim D Fryer, Franklin I Aigbirhio, John T O'Brien, James B Row. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28122879. |
we also examined the 18f-av-1451 autoradiographic binding in post-mortem tissue from patients with alzheimer's disease, progressive supranuclear palsy, and a control case to assess the 18f-av-1451 binding specificity to alzheimer's and non-alzheimer's tau pathology. |
2017-05-29 |
2023-08-13 |
human |
| Luca Passamonti, Patricia Vázquez Rodríguez, Young T Hong, Kieren S J Allinson, David Williamson, Robin J Borchert, Saber Sami, Thomas E Cope, W Richard Bevan-Jones, P Simon Jones, Robert Arnold, Ajenthan Surendranathan, Elijah Mak, Li Su, Tim D Fryer, Franklin I Aigbirhio, John T O'Brien, James B Row. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28122879. |
we suggest that 18f-av-1451 positron emission tomography is a useful biomarker to assess tau pathology in alzheimer's disease and to distinguish it from other tauopathies with distinct clinical and pathological characteristics such as progressive supranuclear palsy. |
2017-05-29 |
2023-08-13 |
human |
| Chiara Giacomelli, Simona Daniele, Claudia Martin. Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases. Biochemical pharmacology. vol 131. 2017-05-29. PMID:28159621. |
β-amyloid (aβ) peptide-containing plaques and intraneuronal neurofibrillary tangles composed of hyperphosphorylated protein tau are the two main neuropathological lesions in alzheimer's disease. |
2017-05-29 |
2023-08-13 |
Not clear |
| Douglas C Dean, Samuel A Hurley, Steven R Kecskemeti, J Patrick O'Grady, Cristybelle Canda, Nancy J Davenport-Sis, Cynthia M Carlsson, Henrik Zetterberg, Kaj Blennow, Sanjay Asthana, Mark A Sager, Sterling C Johnson, Andrew L Alexander, Barbara B Bendli. Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. JAMA neurology. vol 74. issue 1. 2017-05-26. PMID:27842175. |
the accumulation of aggregated β-amyloid and tau proteins into plaques and tangles is a central feature of alzheimer disease (ad). |
2017-05-26 |
2023-08-13 |
Not clear |
| Andreas Hahn, Martin Schain, Maria Erlandsson, Petter Sjölin, Gregory M James, Olof T Strandberg, Douglas Hägerström, Rupert Lanzenberger, Jonas Jögi, Tomas G Olsson, Ruben Smith, Oskar Hansso. Modeling Strategies for Quantification of In Vivo Journal of nuclear medicine : official publication, Society of Nuclear Medicine. vol 58. issue 4. 2017-05-23. PMID:27765859. |
modeling strategies for quantification of in vivo aggregation of hyperphosphorylated tau is a major hallmark of many neurodegenerative diseases, including alzheimer disease (ad). |
2017-05-23 |
2023-08-13 |
Not clear |
| Tadanori Hamano, Norimichi Shirafuji, Chiemi Makino, Shu-Hui Yen, Nicholas M Kanaan, Asako Ueno, Jinya Suzuki, Masamichi Ikawa, Akiko Matsunaga, Osamu Yamamura, Masaru Kuriyama, Yasunari Nakamot. Pioglitazone prevents tau oligomerization. Biochemical and biophysical research communications. vol 478. issue 3. 2017-05-22. PMID:27543203. |
tau aggregation and amyloid β protein (aβ) deposition are the main causes of alzheimer's disease (ad). |
2017-05-22 |
2023-08-13 |
Not clear |
| Jun Yoshitake, Yoshiyuki Soeda, Tomoaki Ida, Akio Sumioka, Misato Yoshikawa, Kenji Matsushita, Takaaki Akaike, Akihiko Takashim. Modification of Tau by 8-Nitroguanosine 3',5'-Cyclic Monophosphate (8-Nitro-cGMP): EFFECTS OF NITRIC OXIDE-LINKED CHEMICAL MODIFICATION ON TAU AGGREGATION. The Journal of biological chemistry. vol 291. issue 43. 2017-05-22. PMID:27601475. |
neurofibrillar tangles caused by intracellular hyperphosphorylated tau inclusion and extracellular amyloid β peptide deposition are hallmarks of alzheimer's disease. |
2017-05-22 |
2023-08-13 |
Not clear |
| Jun Yoshitake, Yoshiyuki Soeda, Tomoaki Ida, Akio Sumioka, Misato Yoshikawa, Kenji Matsushita, Takaaki Akaike, Akihiko Takashim. Modification of Tau by 8-Nitroguanosine 3',5'-Cyclic Monophosphate (8-Nitro-cGMP): EFFECTS OF NITRIC OXIDE-LINKED CHEMICAL MODIFICATION ON TAU AGGREGATION. The Journal of biological chemistry. vol 291. issue 43. 2017-05-22. PMID:27601475. |
no-linked chemical modification on cysteine residues of tau could block tau aggregation, and therefore, increasing 8-nitro-cgmp levels in the brain could become a potential therapeutic strategy for alzheimer's disease. |
2017-05-22 |
2023-08-13 |
Not clear |
| Wolf-Dieter Heiss, Gary A Rosenberg, Alexander Thiel, Rok Berlot, Jacques de Reuc. Neuroimaging in vascular cognitive impairment: a state-of-the-art review. BMC medicine. vol 14. issue 1. 2017-05-22. PMID:27806705. |
pet shows metabolism of glucose and accumulation of amyloid and tau, which is useful in showing abnormal metabolism in alzheimer's disease. |
2017-05-22 |
2023-08-13 |
Not clear |
| Annika van Hummel, Mian Bi, Stefania Ippati, Julia van der Hoven, Alexander Volkerling, Wei S Lee, Daniel C S Tan, Andre Bongers, Arne Ittner, Yazi D Ke, Lars M Ittne. No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapttm1(EGFP)Kit GFP Knockin Mice. PloS one. vol 11. issue 10. 2017-05-19. PMID:27736877. |
several mouse lines with knockout of the tau-encoding mapt gene have been reported in the past; they received recent attention due to reports that tau reduction prevented aβ-induced deficits in mouse models of alzheimer's disease. |
2017-05-19 |
2023-08-13 |
mouse |
| Hanna Cho, Jae Yong Choi, Mi Song Hwang, Jae Hoon Lee, You Jin Kim, Hye Mi Lee, Chul Hyoung Lyoo, Young Hoon Ryu, Myung Sik Le. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. vol 87. issue 4. 2017-05-17. PMID:27358341. |
tau pet in alzheimer disease and mild cognitive impairment. |
2017-05-17 |
2023-08-13 |
Not clear |
| Hanna Cho, Jae Yong Choi, Mi Song Hwang, Jae Hoon Lee, You Jin Kim, Hye Mi Lee, Chul Hyoung Lyoo, Young Hoon Ryu, Myung Sik Le. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. vol 87. issue 4. 2017-05-17. PMID:27358341. |
to investigate the topographical distribution of tau pathology and its effect on functional and structural changes in patients with alzheimer disease (ad) and mild cognitive impairment (mci) by using (18)f-av-1451 pet. |
2017-05-17 |
2023-08-13 |
Not clear |
| Wei Liu, Jingya Zhao, Guangxiu L. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer's disease. Biochemical and biophysical research communications. vol 478. issue 2. 2017-05-17. PMID:27520374. |
mir-106b inhibits tau phosphorylation at tyr18 by targeting fyn in a model of alzheimer's disease. |
2017-05-17 |
2023-08-13 |
Not clear |